The value of early diagnosis and treatment of patients with primary antibody deficiencies

Pharmaceuticals Policy and Law

Volumn 10, Issue , 2008, Pages 147-157

  Wood, Philip ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Antibody deficiency; Common variable immunodeficiency; Immunoglobulin therapy

Indexed keywords

EID: 85013597066     PISSN: 13892827     EISSN: 2210495X     Source Type: Journal    
DOI: None     Document Type: Article

References (64)

1. A. Fasth, Primary immunodeficiency disorders in Sweden: cases among children, 1974-1979, J Clin Immunol 2 (1982), 86-92.
2. A.S. Grumach, A.J. Duarte, R. Bellinati-Pires, A.C. Pastorino, C.M. Jacob, C.L. Diogo, A. Condino-Neto, M. Kirschfink and M.M. Carneiro-Sampaio, Brazilian report on primary immunodeficiencies in children: 166 cases studied over a follow-up time of 15 years, J Clin Immunol 17 (1997), 340-345
3. N. Matamoros Flori, J. Mila Llambi, T. Espanol Boren, S. Raga Borja and G. Fontan Casariego, Primary immunodeficiency syndrome in Spain: first report of the National Registry in Children and Adults, J Clin Immunol 17 (1997), 333-339.
4. A. Stray-Pedersen, T.G. Abrahamsen and S.S. Froland, Primary immunodeficiency diseases in Norway, J Clin Immunol 20 (2000), 477-485.
5. K.W. Baumgart, W.J. Britton, A. Kemp, M. French and D. Roberton, The spectrum of primary immunodeficiency disorders in Australia, J Allergy Clin Immunol 100 (1997), 415-423.
6. R.A. Hermaszewski and A.D. Webster, Primary hypogammaglobulinaemia: a survey of clinical manifestations and complications, Q J Med 86 (1993), 31-42.
7. C. Cunningham-Rundles and C. Bodian, Common variable immunodeficiency: clinical and immunological features of 248 patients, Clin Immunol 92 (1999), 34-48.
8. B. Seymour, J. Miles and M. Haeney, Primary antibody deficiency and diagnostic delay, J Clin Pathol 58 (2005), 546-547.
9. B.S. Eley, J. Hughes, M. Cooper, S. Pienaar and D.W. Beatty, Primary immunodeficiency diseases at Red Cross War Memorial Children’s Hospital, S Afr Med J 87 (1997), 1684-1688.
10. P.E. Hermans, J.A. Diaz-Buxo and J.D. Stobo, Idiopathic late-onset immunoglobulin deficiency. Clinical observations in 50 patients, Am J Med 61 (1976), 221-237.
11. L. Kainulainen, M. Varpula, K. Liippo, E. Svedstrom, J. Nikoskelainen and O. Ruuskanen, Pulmonary abnormalities in patients with primary hypogammaglobulinemia, J Allergy Clin Immunol 104 (1999), 1031-1036.
12. L. Kainulainen, J. Nikoskelainen and O. Ruuskanen, Diagnostic findings in 95 Finnish patients with common variable immunodeficiency, J Clin Immunol 21 (2001), 145-149.
13. O. Ryser, A. Morell and W.H. Hitzig, Primary immunodeficiencies in Switzerland: first report of the national registry in adults and children, J Clin Immunol 8 (1988), 479-485.
14. C. Hausser, J.L. Virelizier, D. Buriot and C. Griscelli, Common variable hypogammaglobulinemia in children. Clinical and immunologic observations in 30 patients, Am J Dis Child 137 (1983), 833-837.
15. L.J. Wang, Y.H. Yang, Y.T. Lin and B.L. Chiang, Immunological and clinical features of pediatric patients with primary hypogammaglobulinemia in Taiwan, Asian Pac J Allergy Immunol 22 (2004), 25-31.
16. J.Wang and C. Cunningham-Rundles, Treatment and outcome of autoimmune hematologic disease in common variable immunodeficiency (CVID), J Autoimmun 25 (2005), 57-62.
17. J.S. Lawrence and J.M. Bremner, Arthritis and hypogammaglobulinaemia. A. Family survey, Scand J Rheumatol 5 (1976), 17-28.
18. I. Dalal, B. Reid, E. Nisbet-Brown and C.M. Roifman, The outcome of patients with hypogammaglobulinemia in infancy and early childhood, J Pediatr 133 (1998), 144-146.
19. P. Wood, S. Stanworth, J. Burton, A. Jones, D.G. Peckham, T. Green, C. Hyde and H. Chapel, Recognition, clinical diagnosis and management of patients with primary antibody deficiencies: a systematic review, Clin Exp Immunol 149 (2007), 410-423.
20. Hypogammaglobulinaemia. MWPo. 1971. Hypogammaglobulinaemia in the United Kingdom. Medical Research Council, Special Report Series London HMSO 310 (2007).
21. Z.A.E. Liu and C. Hyde, The effectiveness and cost-effectiveness of immunoglobulin replacement therapy for primary immunodeficiency and chronic lymphocytic leukaemia: a systematic review and economic evaluation. West Midlands Health Technolopgy Assessment Group, Dept of Public Health & Epidemiology, University of Birmingham, 2006, 54.
22. C.M. Roifman, H. Schroeder, M. Berger, R. Sorensen, M. Ballow, R.H. Buckley, A. Gewurz, P. Korenblat, G. Sussman and G. Lemm, Comparison of the efficacy of IGIV-C, 10% (caprylate/ chromatography) and IGIV-SD, 10% as replacement therapy in primary immune deficiency. A randomized double-blind trial, Int Immunopharmacol 3 (2003), 1325-1333.
23. A. Aghamohammadi, M. Moin, A. Farhoudi, N. Rezaei, Z. Pourpak, M. Movahedi, M. Gharagozlou, M. Nabavi and A. Shahrokhi, Efficacy of intravenous immunoglobulin on the prevention of pneumonia in patients with agammaglobulinemia, FEMS Immunol Med Microbiol 40 (2004), 113-118.
24. J. de Gracia, M. Vendrell, A. Alvarez, E. Pallisa, M.J. Rodrigo, D. de la Rosa, F. Mata, J. Andreu and F. Morell, Immunoglobulin therapy to control lung damage in patients with common variable immunodeficiency, Int Immunopharmacol 4 (2004), 745-753.
25. P.J. Busse, S. Razvi and C. Cunningham-Rundles, Efficacy of intravenous immunoglobulin in the prevention of pneumonia in patients with common variable immunodeficiency, J Allergy Clin Immunol 109 (2002), 1001-1004.
26. C. Cunningham-Rundles, F.P. Siegal, E.M. Smithwick, A. Lion-Boule, S. Cunningham-Rundles, J. O’Malley, S. Barandun and R.A. Good, Efficacy of intravenous immunoglobulin in primary humoral immunodeficiency disease, Ann Intern Med 101 (1984), 435-439.
27. P. Quartier, M. Debre, J. De Blic, R. de Sauverzac, N. Sayegh, N. Jabado, E. Haddad, S. Blanche, J.L. Casanova, C.I. Smith, F. Le Deist, G. de Saint Basile andA. Fischer, Early and prolonged intravenous immunoglobulin replacement therapy in childhood agammaglobulinemia: a retrospective survey of 31 patients, J Pediatr 134 (1999), 589-596.
28. S. Skull and A. Kemp, Treatment of hypogammaglobulinaemia with intravenous immunoglobulin, 1973-1993, Arch Dis Child 74 (1996), 527-530.
29. C.M. Roifman, H. Levison and E.W. Gelfand, High-dose versus low-dose intravenous immunoglobulin in hypogammaglobulinaemia and chronic lung disease, Lancet 1 (1987), 1075-1077.
30. H.W. Eijkhout, J.W. van Der Meer, C.G. Kallenberg, R.S. Weening, J.T. van Dissel, L.A. Sanders, P.F. Strengers, H. Nienhuis and P.T. Schellekens, The effect of two different dosages of intravenous immunoglobulin on the incidence of recurrent infections in patients with primary hypogammaglobulinemia. A randomized, double-blind, multicenter crossover trial, Ann Intern Med 135 (2001), 165-174.
31. E. Galli, C. Barbieri, A. Cantani, A. Solano, M.A. Longhi and L. Businco, Treatment with gammaglobulin preparation for intravenous use in children with humoral immunodeficiency: clinical and immunologic follow-up, Ann Allergy 64 (1990), 147-150.
32. A.J. Ammann, R.F. Ashman, R.H. Buckley, W.R. Hardie, H.J. Krantmann, J. Nelson, H. Ochs, E.R. Stiehm, T. Tiller, D.W. Wara and R. Wedgwood, Use of intravenous gamma-globulin in antibody immunodeficiency: results of a multicenter controlled trial, Clin Immunol Immunopathol 22 (1982), 60-67.
33. N.D. Garbett, D.C. Currie and P.J. Cole, Comparison of the clinical efficacy and safety of an intramuscular and an intravenous immunoglobulin preparation for replacement therapy in idiopathic adult onset panhypogammaglobulinaemia, Clin Exp Immunol 76 (1989), 1-7.
34. A. Plebani, A. Soresina, R. Rondelli, G.M. Amato, C. Azzari, F. Cardinale, G. Cazzola, R. Consolini, D. De Mattia, G. Dell’Erba, M. Duse, M. Fiorini, S. Martino, B. Martire, M. Masi, V. Monafo, V. Moschese, L.D. Notarangelo, P. Orlandi, P. Panei, A. Pession, M.C. Pietrogrande, C. Pignata, I. Quinti, V. Ragno, P. Rossi, A. Sciotto and A. Stabile, Clinical, immunological, and molecular analysis in a large cohort of patients with X-linked agammaglobulinemia: an Italian multicenter study, Clin Immunol 104 (2002), 221-230.
35. E. Halliday, J. Winkelstein and A.D. Webster, Enteroviral infections in primary immunodeficiency (PID): a survey of morbidity and mortality, J Infect 46 (2003), 1-8.
36. A. Franz, A.D. Webster, P.M. Furr and D. Taylor-Robinson, Mycoplasmal arthritis in patients with primary immunoglobulin deficiency: clinical features and outcome in 18 patients, Br J Rheumatol 36 (1997), 661-668.
37. G.P. Spickett, T. Askewand H.M. Chapel, Management of primary antibody deficiency by consultant immunologists in the United Kingdom: a paradigm for other rare diseases, Qual Health Care 4 (1995), 263-268.
38. J. Blore and M.R. Haeney, Primary antibody deficiency and diagnostic delay, Bmj 298 (1989), 516-517.
39. H.M. Chapel, Consensus on diagnosis and management of primary antibody deficiencies. Consensus Panel for the Diagnosis and Management of Primary Antibody Deficiencies, Bmj 308 (1994), 581-585.
40. C. Cunningham-Rundles, Clinical and immunologic analyses of 103 patients with common variable immunodeficiency, J Clin Immunol 9 (1989), 22-33.
41. C. Sordet, A. Cantagrel, T. Schaeverbeke and J. Sibilia, Bone and joint disease associated with primary immune deficiencies, Joint Bone Spine 72 (2005), 503-514.
42. A.H. Lee, A.I. Levinson and H.R. Schumacher Jr., Hypogammaglobulinemia and rheumatic disease, Semin Arthritis Rheum 22 (1993), 252-264.
43. K. Washington, T.T. Stenzel, R.H. Buckley and M.R. Gottfried, Gastrointestinal pathology in patients with common variable immunodeficiency and X-linked agammaglobulinemia, Am J Surg Pathol 20 (1996), 1240-1252.
44. K. Teahon, A.D. Webster, A.B. Price, J. Weston and I. Bjarnason, Studies on the enteropathy associated with primary hypogammaglobulinaemia, Gut 35 (1994), 1244-1249.
45. U.H. Ziegner, R.H. Kobayashi, C. Cunningham-Rundles, T. Espanol, A. Fasth, A. Huttenlocher, P. Krogstad, L. Marthinsen, L.D. Notarangelo, S. Pasic, C.H. Rieger, P. Rudge, R. Sankar, A.O. Shigeoka, E.R. Stiehm, K.E. Sullivan, A.D.Webster and H.D. Ochs, Progressive neurodegeneration in patients with primary immunodeficiency disease on IVIG treatment, Clin Immunol 102 (2002), 19-24.
46. A.H. Filipovich, A. Mathur, D. Kamat, J.H.Kersey and R.S. Shapiro, Lymphoproliferative disorders and other tumors complicating immunodeficiencies, Immunodeficiency 5 (1994), 91-112.
47. L. Mellemkjaer, L. Hammarstrom, V. Andersen, J. Yuen, C. Heilmann, T. Barington, J. Bjorkander and J.H. Olsen, Cancer risk among patients with IgA deficiency or common variable immunodeficiency and their relatives: a combined Danish and Swedish study, Clin Exp Immunol 130 (2002), 495-500.
48. L.J. Kinlen, A.D.Webster, A.G. Bird, R. Haile, J. Peto, J.F. Soothill and R.A. Thompson, Prospective study of cancer in patients with hypogammaglobulinaemia, Lancet 1 (1985), 263-266.
49. C. Cunningham-Rundles, F.P. Siegal, S. Cunningham-Rundles and P. Lieberman, Incidence of cancer in 98 patients with common varied immunodeficiency, J Clin Immunol 7 (1987), 294-299.
50. A. Gardulf, H. Bjorvell, R. Gustafson, L. Hammarstrom and C.I. Smith, The life situations of patients with primary antibody deficiency untreated or treated with subcutaneous gammaglobulin infusions, Clin Exp Immunol 92 (1993), 200-204.
51. M. Bergner, R.A. Bobbitt, W.B. Carter and B.S. Gilson, The Sickness Impact Profile: development and final revision of a health status measure, Med Care 19 (1981), 787-805.
52. V. Howard, J.M. Greene, S. Pahwa, J.A.Winkelstein, J.M. Boyle, M. Kocak and M.E. Conley, The health status and quality of life of adults with X-linked agammaglobulinemia, Clin Immunol 118 (2006), 201-208.
53. J. Ware, Jr., M. Kosinski and S.D. Keller, A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity, Med Care 34 (1996), 220-233.
54. H.M. Lederman and J.A. Winkelstein, X-linked agammaglobulinemia: an analysis of 96 patients, Medicine (Baltimore) 64 (1985), 145-156.
55. Immune Deficiency Foundation. 2003. Primary Immune Deficiency Diseases in America - The First National Survey of Patients and Specialists.
56. H. Tcheurekdjian, T. Palermo and R. Hostoffer, Quality of life in common variable immunodeficiency requiring intravenous immunoglobulin therapy, Ann Allergy Asthma Immunol 93 (2004), 160-165.
57. A. Gardulf, V. Andersen, J. Bjorkander, D. Ericson, S.S. Froland, R. Gustafson, L. Hammarstrom, M.B. Jacobsen, E. Jonsson, G. Moller et al., Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: safety and costs, Lancet 345 (1995), 365-369.
58. B. Hogy, H.O.Keinecke and M. Borte, Pharmacoeconomic evaluation of immunoglobulin treatment in patients with antibody deficiencies from the perspective of the German statutory health insurance, Eur J Health Econ 6 (2005), 24-29.
59. F.B. Dong, S.W. Sorensen, D.L. Manninen, T.J. Thompson, V. Narayan, C.E. Orians, E.W. Gregg, R.C. Eastman, E.J. Dasbach, W.H. Herman, J.M. Newman, A.S. Narva, D.J. Ballard and M.M. Engelgau, Cost effectiveness of ACE inhibitor treatment for patients with type 1 diabetes mellitus, Pharmacoeconomics 22 (2004), 1015-1027.
60. G. Kobelt, L. Jonsson, C. Miltenburger and B. Jonsson, Cost-utility analysis of interferon beta-1B in secondary progressive multiple sclerosis using natural history disease data, Int J Technol Assess Health Care 18 (2002), 127-138.
61. B. Lippert, K. Berger, E. Berntorp, P. Giangrande, M. van den Berg, W. Schramm and U. Siebert, Cost effectiveness of haemophilia treatment: a cross-national assessment, Blood Coagul Fibrinolysis 16 (2005), 477-485.
62. J.R. Spalding and J. Hay, Cost effectiveness of tumour necrosis factor-alpha inhibitors as first-line agents in rheumatoid arthritis, Pharmacoeconomics 24 (2006), 1221-1232.
63. I. Jaisson-Hot, B. Flourie, L. Descos and C. Colin, Management for severe Crohn’s disease: a lifetime cost-utility analysis, Int J Technol Assess Health Care 20 (2004), 274-279.
64. W.C.Winkelmayer, M.C.Weinstein, M.A. Mittleman, R.J. Glynn and J.S. Pliskin, Health economic evaluations: the special case of end-stage renal disease treatment, Med Decis Making 22 (2002), 417-430.